GlobeNewswire Inc.··SanofiSanofi's Rezurock Wins EU Approval for Chronic Graft-Versus-Host Disease
European Commission approves Sanofi's Rezurock for chronic GvHD treatment in patients 12+, based on 74% response rate from Phase 2 trials.
SNYorphan drugEU approval